• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10
    • Buyers' Guide
    • Events
    • Microsites
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10
  • Buyers' Guide
  • Events
  • Microsites
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    Development Options: Orthopedic Device Design

    I, Surgical Robot

    Printer-Friendly: An Additive Manufacturing Update

    Instrumentation Innovations: A Review of Instrument Manufacturing

    The Total Package: Packaging and Sterilization for Orthopedics
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    Orthopedic Innovators
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury

    Google Executive Joins SeaSpine's Board of Directors

    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility

    Study: Spinal Fixation Rods Can Improve Patient Outcomes

    Orchid Welcomes New CFO
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility

    Study: Spinal Fixation Rods Can Improve Patient Outcomes

    Usability, Sustainability Becoming More Relevant in Medtech Packaging

    FDA Approves NuVasive's Simplify Disc for Two-Level Cervical Total Disc Replacement

    FDA Clears Orthofix's 3D-Printed Titanium Cervical Spacer System
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Usability, Sustainability Becoming More Relevant in Medtech Packaging

    Orthopedic Solutions from Man’s Best Friend

    The FDA’s Flip-Flop on Hyaluronic Acid

    HSS, Zimmer Biomet's Solution for the Episode of Orthopedic Care

    Rising to the Challenge: Q&A with AAOS Second VP Dr. Savoie
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    ARCH Medical Solutions

    Edge International/Supra Alloys

    Lincotek Medical

    Lyons

    Donatelle
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Columns

    The ABCs of Reimbursement for Breakthrough Devices

    At the cross-section of BDD status are device reimbursement strategy considerations.

    Tonya Dowd, MPH and Simran Madhani, MCRA03.13.20
    Since its inception, the U.S. Food and Drug Administration’s (FDA) Breakthrough Device Designation (BDD) program has become a coveted indication with medical device manufacturers. Besides giving companies a way to engage early and often with the agency for insight into a full regulatory plan, BDD allows firms to classify their technology as truly novel.

    At the cross-section of BDD status are device reimbursement strategy considerations. In particular, recent changes from the Centers for Medicare and Medicaid Services (CMS) to grant additional payment—typically independent of BDD status—are often assumed to be the next and final step to establishing reimbursement for a device.

    This article will explore reimbursement implications and considerations for BDD products and discuss key misperceptions in the field, taking into account the three key reimbursement fundamentals: coding, payer coverage, and payment. These factors are interrelated but not interdependent.

    BDD Program
    In 2016, Congressional law established the BDD program, which was published in December 2018. The program provides patients and healthcare providers with timely access to new medical devices and innovations, replacing the Expedited Access Pathway established in 2015. Breakthrough devices under the program receive priority review and a possible expedited path to market. All BDD requests must be made in a separate “Q-Sub” before a marketing submission. The FDA might ask for additional information (usually within 30 days) and decide on a BDD application within 60 days; companies can request to withdraw from the program at any time. The FDA may withdraw designation upon written notice if the BDD-awarded product is no longer eligible for the classification or the information submitted in the designation request contains an untrue statement or omits material information. Manufacturers with devices that have PMA, 510(k), or De Novo marketing submissions can submit BDD requests. Products, however, must meet the following criterion to be granted BDD.

    Criterion 1: Devices must provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions.

    Criterion 2: The device must meet one of the following: the device represents breakthrough technologies; no approved or cleared alternative exists for the device; the device offers significant advantages over existing approved or cleared alternatives; and device availability is in the best interest of patients.

    There are many benefits of obtaining BDD, but the designation itself is not a guarantee of a more streamlined path to reimbursement or easier market access. Careful analysis of the health economic landscape is key to developing an optimized reimbursement strategy and ensuring the true benefits of Breakthrough designation are realized.

    Recent CMS Payment Methodologies Changes
    Breakthrough products now have an alternate way to qualify for device pass-through payment status under the Hospital Outpatient Prospective Payment System. For applications received on or after Jan. 1, 2020, CMS is no longer evaluating BDD products in terms of the current substantial clinical improvement criteria, and all breakthrough devices now qualify for the quarterly approval process for device pass-through payment.

    Under the 2020 Inpatient Prospective Payment System (IPPS) rule, CMS finalized an alternative New Technology Add-On Payment (NTAP) eligibility pathway for transformative new devices. BDD products that receive FDA marketing authorization are considered new and not substantially similar to an existing technology. CMS acknowledges breakthrough devices will not have an adequate amount of time to demonstrate clinical improvement so BDD products do not have to meet the newness or substantial improvement criteria under the NTAP program (but they must meet cost criteria).

    The new medical service or technology add-on payment policy under the IPPS provides additional payments for cases with relatively high costs involving eligible new medical services or technologies, while preserving some of the incentives inherent under an average-based prospective payment system. This additional payment is designed to protect the hospital from large financial losses due to unusually expensive cases. Any eligible outlier payment is added to the DRG-adjusted base payment rate, plus any new technology or medical service add-on adjustment. A medical service or technology may continue to be considered ‘‘new’’ for purposes of new technology add-on payments within two or three years, after which data begin to become available reflecting the inpatient hospital code assigned to the new service or technology.

    For FY 2020, CMS agreed with comments that capping the add-on payment amount at 50 percent might no longer provide a sufficient incentive for use of the technology. As such, for discharges on or after Oct. 1, 2019, CMS finalized the add-on payment be equal to the lesser of the following under the Hospital Inpatient Prospective Payment System in Medicare Part A: 65 percent of the cost of the new medical services or technology, or 65 percent of the amount by which the costs of the case exceed the standard DRG payment.

    As of Sept. 30, 2018, FDA has granted 71 BDD requests out of 100 total applications received with a final decision. An additional 26 devices from precursor programs were included, so a total of 97 devices are in the BDD program.1

    The FDA has received 13 marketing BDD submissions for FY20—eight PMAs, three de novo clearances, and two 510(k) clearances. Of the 13 total submissions, FDA has cleared two 510(k)s, granted two de novo requests, and approved five PMAs.

    BDD Misconceptions
    The key reimbursement fundamentals are coding, coverage, and payment. Coding is used to identify what procedure or device is used on a submitted claim to a third party payer; third party payers determine coverage, based on whether the procedure or device is “medically necessary or reasonable and necessary” to treat a condition; and payment is given to a provider for a procedure or device.

    Keeping these fundamentals in mind, it is important for manufacturers and providers to understand a BDD designation does not necessarily satisfy all three criteria for a device. Of the aforementioned payment methods, both NTAP and pass-through payments are temporary, and neither guarantees coverage. According to Medicare, “The fact that a drug, device, procedure, or service is assigned a HCPCS code and a payment rate under the Outpatient payment system does not imply coverage by the Medicare program, but indicates only how the product, procedure, or service may be paid if covered by the program. Medicare Administrative Contractors (MACs) determine whether a drug, device, procedure, or other service meets all program requirements for coverage. For example, MACs determine that it is reasonable and necessary to treat the beneficiary’s condition and whether it is excluded from payment.”2

    It’s important manufacturers understand that NTAPs only apply to the IPPS; in other words, procedures that use technologies in the hospital inpatient setting (i.e., 24-hour-plus), while, Transitional Pass Through Payments only apply to the HOPPS, or procedures in an outpatient setting (less than 24 hours). NTAP or pass-through payments do not automatically lead to reimbursement.

    Furthermore, these payment methodologies only apply to Medicare Fee-For-Service (FFS) payment methodologies and are not necessarily applicable to provider contracts with commercial payers.

    PROCEPT BioRobotics’ AquaBeam Robotic System, for example, received CMS approval for device pass-through payment starting Jan. 1, 2020, as part of the OPPS ruling.3 Aquabeam is the first FDA-approved surgical robot providing autonomous removal of prostate tissue in men suffering from lower urinary tract symptoms due to benign prostatic hyperplasia or enlarged prostate.4 CMS had already approved NTAP for AquaBeam in its FY19 IPPS rule.5 Now AquaBeam has both NTAP for inpatient procedures and a pass-through payment for outpatient procedures. AquaBeam has the codes and the payment, but it has yet to establish positive commercial coverage. Aetna considers aquablation (AquaBeam, water jet-hydrodissection) for the treatment of benign prostatic hypertrophy experimental and investigational because the effectiveness of this intervention has not been established by peer-reviewed medical literature.6

    Likewise, the FDA gave Impulse Dynamic’s OPTIMIZER System a breakthrough device designation in March 2019 because it treats a life-threatening disease (heart failure), and addresses an unmet medical need.7 CMS followed suit and qualified the OPTIMIZER System for device pass-through payment status because it met the substantial clinical improvement criterion under the new alternative pathway.3 But even after receiving breakthrough designation and pass-through payment, the OPTIMIZER System is still considered “experimental and investigational because the effectiveness of this approach has not been established.”8

    Coding, coverage, and payment are all interrelated, and establishing reimbursement for new technologies in the United States is not a linear process. While coding is the link between coverage and payment, technology innovators should not expect payment or coverage simply because a code has been established.

    The notion that reimbursement, regulatory, clinical, or evidence development strategies are separate and distinct processes is flawed. One informs the other, and these strategies should be developed and carried out in parallel.

    New technology innovators are encouraged to adopt a new narrative. A reimbursement and market access strategy developed early in the product lifecycle is as important as a regulatory strategy; by not planning early, technology innovators compromise the successful commercial market adoption for their technology.

    It is imperative to plan reimbursement and market access strategy early in the product lifecycle or the expedited FDA pathway. Medicare may provide additional payment in the short term, but Medicare and commercial plans will still need evidence for coverage and payment in the long term. 

    References
    1. bit.ly/odt200321
    2. CMS Manual System: Department of Health & Human Services (DHHS) Pub 100-04 Medicare Claims Processing
    3. bit.ly/odt200323
    4. bit.ly/odt200324
    5. bit.ly/odt200325
    6. bit.ly/odt200326
    7. bit.ly/odt200327
    8. bit.ly/odt200308


    Tonya Dowd, MPH, is leader in healthcare economics, reimbursement, and market access. With over 25 years of experience and expertise, she possesses a global understanding of healthcare payment and delivery systems and reimbursement and coverage processes for new and emerging medical technologies.

    Simran Madhani advises on healthcare policy, coverage guidelines, and clinical literature to provide reimbursement pathways, solutions, and strategies, compliant with AMA and CMS guidelines, for a diverse range of clients. She develops coverage landscape analyses, strategic reimbursement plans, payor messaging tools, and clinical literature briefs for client reimbursement needs. 
    Related Searches
    • medical devices
    • regulatory
    • development
    • medical device manufacturers

    Related Columns

    • An Orthopedic Giant Re-emerges: DJO to Return?

      An Orthopedic Giant Re-emerges: DJO to Return?

      At the beginning of March, diversified tech firm Colfax Corp. proclaimed its intention to split in two.
      Sam Brusco, Associate Editor 03.16.21

    • Actual Orthopedics Medical and Surgical Supply Costs for Care Centers

      Actual Orthopedics Medical and Surgical Supply Costs for Care Centers

      According to a 2018 clinical journal article, U.S. hospitals spent approximately $200 billion on medical devices.
      Maria Shepherd, President and Founder, Medi-Vantage 03.16.21

    • Show Time: Here’s What a Year of No Tradeshows Meant for Small Businesses

      Show Time: Here’s What a Year of No Tradeshows Meant for Small Businesses

      For small businesses, trade shows are a critical part of developing new business as well as maintaining contacts.
      Dawn A. Lissy, Founder & President, Empirical 03.16.21


    • A Summary of Key Provisions Within CMS’ Final MCIT Rule

      A Summary of Key Provisions Within CMS’ Final MCIT Rule

      MCIT is available not only for new breakthrough devices but also for products that received this designation within the last two years.
      John D. McDermott Jr., Senior Director, Reimbursement Strategy, MCRA LLC 03.16.21

    • Prototyping
      Intelligent Iteration: The Benefits of Prototyping Rapidly

      Intelligent Iteration: The Benefits of Prototyping Rapidly

      You don’t need to make a full prototype with all features, finishes, and functions included in order to evaluate the design and gain valuable information.
      Victoria Trafka, President and Principal Engineer, Engineering & Quality Solutions Inc. 03.16.21

    • Design
      A Holistic Approach to Early Product Development

      A Holistic Approach to Early Product Development

      Regulatory requirements and limitations have a pronounced impact on new product development in the medical device industry.
      Bryan Brosseau, Founder and Principal Consultant, Brosseau Consulting LLC 03.16.21


    • Striving to Attain a Gain on the Pain

      Striving to Attain a Gain on the Pain

      A growing number of orthopedic patients are wrestling with fear, perhaps fueled in part by variant virus strains believed to be more contagious.
      Michael Barbella, Managing Editor 02.08.21

    • Rethink Your Orthopedic ASC Strategy, Part 1

      Rethink Your Orthopedic ASC Strategy, Part 1

      ASCs have adopted a strategy to focus on predictable, low-risk procedures with lower complication rates in an out-of-hospital setting.
      Maria Shepherd, President and Founder, Medi-Vantage 02.08.21

    • Pandemic-Level Playing Field: How COVID-19 Made Space for Progress

      Pandemic-Level Playing Field: How COVID-19 Made Space for Progress

      Pandemic restrictions may have diminished certain advantages large companies hold over small and mid-sized competitors.
      Dawn A. Lissy, Founder & President, Empirical 02.08.21


    • Tips for Reigniting Your MDR/IVDR Preparation

      Tips for Reigniting Your MDR/IVDR Preparation

      To get the MDR/IVDR preparation ball rolling again, here are four processes to help refocus on achieving compliance with the updated regulations.
      Nicolle Cannon, Founder and CEO, Cannon Quality Group LLC 02.08.21

    • Biologics
      An FDA Regulatory Perspective on Bone Grafts

      An FDA Regulatory Perspective on Bone Grafts

      There are various bone grafts with different composition, source, mechanical strength, and functional biological mechanisms.
      Mehdi Kazemzadeh-Narbat, Ph.D., Senior Associate, Regulatory Affairs, MCRA LLC 02.08.21

    • Packaging & Sterilization
      Building a More Transparent Healthcare Supply Chain with UDI

      Building a More Transparent Healthcare Supply Chain with UDI

      The FDA’s 2013 Unique Device Identification (UDI) Rule sets specific requirements for medical device labeling to improve traceability and patient safety.
      Beth Wells, Senior Director, Community Engagement, Healthcare, GS1 US 02.08.21


    • Stryker Strikes Back After Pandemic Slump

      Stryker Strikes Back After Pandemic Slump

      Late last year, Stryker announced it would snap up Wright Medical to fortify its position in the trauma and extremities markets.
      Sam Brusco, Associate Editor 11.18.20

    • Large Joint
      Obesity and the Impact on Hip and Knee Implants

      Obesity and the Impact on Hip and Knee Implants

      Obesity causes multiple health issues, and the COVID-19 pandemic is only adding to the problem.
      Maria Shepherd, President and Founder, Medi-Vantage 11.18.20

    • Virtually the Same? The Challenges of Online Conferences

      Virtually the Same? The Challenges of Online Conferences

      Like everyone else on the planet, I’m turning increasingly to virtual solutions to our physical challenges in the midst of a pandemic.
      Dawn A. Lissy, Founder & President, Empirical 11.18.20


    Trending
    • Six Advantages Of Machined Polymer Components Over Metals
    • Abbott's Proclaim XR Neurostimulator Reduces Chronic Pain
    • Mini MRI For Hand And Wrist Imaging Can Be Used Nearly Anywhere
    • Cementless Hip Implants Are Gradually Losing Their Popularity In Europe
    • Arch Acquires Jade Precision Medical Components And Jade Equipment Corporation
    Breaking News
    • New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    • Google Executive Joins SeaSpine's Board of Directors
    • HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    • Study: Spinal Fixation Rods Can Improve Patient Outcomes
    • Orchid Welcomes New CFO
    View Breaking News >
    CURRENT ISSUE

    March/April 2021

    • Development Options: Orthopedic Device Design
    • I, Surgical Robot
    • Printer-Friendly: An Additive Manufacturing Update
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies to Sponsor and Exhibit at the North American Pultrusion Conference 2021
    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    The Honest Company Files for IPO
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login